Skip to main content
. 2020 Feb 19;8(1):e000933. doi: 10.1136/bmjdrc-2019-000933

Table 1.

Baseline characteristics of the ESTHER diabetes subcohort and the DIANA cohort

Baseline characteristics Cohorts
ESTHER (n=1045),

N (%)*
DIANA (n=1101),

N (%)*
Age (years)
 <60 57 (5.4) 206 (18.7)
 60–<70 441 (42.2) 313 (28.4)
 70–<80 473 (45.3) 455 (41.4)
 ≥80 74 (7.1) 127 (11.5)
Sex
 Male 541 (51.8) 605 (54.9)
 Female 504 (48.2) 496 (45.6)
Education†
 Low 816 (78.1) 806 (73.2)
 Medium 130 (12.4) 197 (17.9)
 High 99 (9.5) 98 (9.9)
BMI (kg/m²)
 <25 142 (13.6) 149 (13.5)
 25–<30 466 (44.6) 431 (39.1)
 30–<35 305 (29.2) 340 (30.9)
 35–<40 92 (8.8) 108 (9.9)
 ≥40 40 (3.8) 73 (6.6)
Smoking
 Never smoker 503 (48.1) 531 (48.2)
 Former smoker 453 (43.4) 441 (40.1)
 Current smoker, smoking 0–15 g tobacco/day 45 (4.3) 65 (5.9)
 Current smoker, smoking >15 g tobacco/day 44 (4.2) 64 (5.8)
Alcohol consumption‡
 Abstainer 466 (44.5) 402 (36.6)
 Low consumption 533 (51.0) 629 (57.1)
 Moderate consumption 33 (3.2) 48 (4.3)
 High consumption 13 (1.2) 22 (2.0)
Physical activity§
 Inactive 582 (55.7) 277 (25.2)
 Active 463 (44.3) 824 (74.8)
Daily vegetable consumption
 No 852 (81.6) 735 (66.7)
 Yes 193 (18.4) 366 (33.3)
Daily fruit consumption
 No 417 (39.9) 365 (33.2)
 Yes 628 (60.1) 736 (66.8)
HbA1c (%)
 <6 227 (21.7) 151 (13.7)
 6–<7 489 (46.8) 575 (52.2)
 7–<8 252 (24.1) 241 (21.9)
 ≥8 77 (7.4) 134 (12.2)
Diabetes medication
 No 348 (33.3) 276 (25.1)
 Oral antidiabetics 501 (47.9) 592 (53.8)
 Insulin 196 (18.8) 233 (21.1)
Time since diabetes diagnosis (years)
 <5 445 (42.6) 358 (32.5)
 5–<10 325 (31.1) 300 (27.3)
 10–<20 205 (19.6) 346 (31.4)
 ≥20 70 (6.7) 97 (8.8)
Renal dysfunction¶
 No 748 (71.6) 800 (72.6)
 Yes 297 (28.4) 301 (27.4)
Hypertension
 No 299 (28.6) 238 (21.6)
 Yes 746 (71.4) 863 (78.4)
History of stroke
 No 927 (88.7) 1035 (94.0)
 Yes 128 (11.3) 66 (6.0)
History of myocardial infarction
 No 916 (87.7) 1007 (91.5)
 Yes 129 (12.3) 94 (8.5)
Coronary heart disease
 No 737 (70.5) 897 (81.5)
 Yes 308 (29.5) 203 (18.5)
Heart failure
 No 828 (79.2) 963 (87.5)
 Yes 217 (20.8) 138 (12.5)
History of cancer
 No 907 (86.8) 990 (89.9)
 Yes 138 (13.2) 111 (10.1)
Total cholesterol (mg/dL)
 <200 379 (36.3) 392 (35.6)
 200–<280 568 (54.3) 568 (51.6)
 ≥280 98 (9.4) 141 (12.8)
HDL cholesterol (mg/dL)
 <40 158 (15.1) 268 (24.4)
 40–<80 840 (80.4) 772 (70.1)
 ≥80 47 (4.5) 61 (5.5)
CRP (mg/L)
 ≤3 606 (58.0) 658 (59.8)
 >3–≤10 338 (32.3) 349 (31.7)
 >10 101 (9.7) 94 (8.5)
D-ROM (Carr unit)
 ≤400 805 (77.0) 677 (61.5)
 >400 240 (23.0) 425 (38.5)

*Numbers shown were drawn from a data set with imputed missing values.

†Definition of low, medium and high education were ≤9, 10–11 and ≥12 years of school education, respectively.

‡Definition of low alcohol consumption: women >0–<20 and men >0–<40 g ethanol per day. Definition of moderate alcohol consumption: women ≥20–<40 and men ≥40 –<60 g ethanol per day. Definition of high alcohol consumption: women ≥40 and men ≥60 g ethanol per day.

§Inactive: 0 hour of vigorous physical activity/week; active: >0 hour of vigorous physical activity/week.

¶Renal dysfunction was defined by an eGFR <60 mL/min/1.73 m².

BMI, body mass index; CRP, C reactive protein; DIANA, Diabetes mellitus: Neue Wege der Optimierung der allgemeinärztlichen Betreuung; D-ROM, Diacron’s reactive oxygen metabolites; eGFR, estimated glomerular filtration rate; ESTHER, Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung; HbA1c, glycated haemoglobin A1c; HDL, high-density lipoprotein.